Alliance Pharma’s H1 interims are relatively robust, with trading conforming to recent commentary. Whilst there has been an impact in some areas of the business in H1 (Prescription Medicine) as expected per the trading update in July, the rest of the business particularly Kelo-cote, has proved very resilient and highlights the defensive nature of the business, and underlying adj. PBT (excl. amortisation and impairment charges) was solid in H1 2020 at £16.3m (+7% YoY). We anticipat
22 Sep 2020
Interims – guidance reiterated. We reintroduce forecast & move to Buy
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Interims – guidance reiterated. We reintroduce forecast & move to Buy
Alliance Pharma plc (APH:LON) | 37.0 0 0.3% | Mkt Cap: 199.8m
- Published:
22 Sep 2020 -
Author:
Edward Thomason -
Pages:
4
Alliance Pharma’s H1 interims are relatively robust, with trading conforming to recent commentary. Whilst there has been an impact in some areas of the business in H1 (Prescription Medicine) as expected per the trading update in July, the rest of the business particularly Kelo-cote, has proved very resilient and highlights the defensive nature of the business, and underlying adj. PBT (excl. amortisation and impairment charges) was solid in H1 2020 at £16.3m (+7% YoY). We anticipat